Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Cash from Operations: 2020-2025

Historic Cash from Operations for Journey Medical (DERM) over the last 5 years, with Sep 2025 value amounting to -$2.4 million.

  • Journey Medical's Cash from Operations fell 105.96% to -$2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.9 million, marking a year-over-year increase of 85.89%. This contributed to the annual value of -$9.1 million for FY2024, which is 274.18% down from last year.
  • As of Q3 2025, Journey Medical's Cash from Operations stood at -$2.4 million, which was down 152.97% from -$942,000 recorded in Q2 2025.
  • In the past 5 years, Journey Medical's Cash from Operations registered a high of $18.7 million during Q3 2023, and its lowest value of -$16.5 million during Q4 2023.
  • Moreover, its 3-year median value for Cash from Operations was -$1.2 million (2024), whereas its average is -$913,091.
  • Its Cash from Operations has fluctuated over the past 5 years, first soared by 357.44% in 2023, then plummeted by 425.00% in 2024.
  • Quarterly analysis of 5 years shows Journey Medical's Cash from Operations stood at -$3.2 million in 2021, then declined by 19.65% to -$3.8 million in 2022, then crashed by 330.66% to -$16.5 million in 2023, then surged by 113.47% to $2.2 million in 2024, then plummeted by 105.96% to -$2.4 million in 2025.
  • Its Cash from Operations was -$2.4 million in Q3 2025, compared to -$942,000 in Q2 2025 and -$2.8 million in Q1 2025.